patients with advanced PC. 7, 8 Prostate-specific antigen (PSA)
is an unreliable marker of disease activity since neuroendocrine cells do not express it, contributing to late-stage recognition of t-NEPC during ADT and its overall poor prognosis. Symptoms are generally related to obstruction, with episodes of urinary retention and hematuria. 9 Based on the treatment paradigm for small-cell lung cancer, as the prototype of aggressive neuroendocrine tumors, patients are often treated with platinum-based chemotherapy and radiation as appropriate. However, despite initial responses, rapid progression is the rule and no standard second line or curative therapy is available. 10 This report presents a case of a complete metabolic regression of t-NEPC after sequential treatment with the experimental macrophage M1 repolarizing agent, RRx-001, dosed intravenously once weekly until progression, followed by reintroduced carboplatin and etoposide on a multi-arm, multi-center clinical trial called QUADRUPLE THREAT (NCT02489903).
| CASE PRESENTATION
The subject of this case report is a 65-year-old male diagnosed with pT3a, N0, Mx, Gleason score 9 (4 + 5) adenocarcinoma of the prostate diagnosed in 2008, for which he received radical retropubic prostatectomy (RRP) followed by external beam radiation therapy (EBRT). Due to a prostate-specific antigen doubling time of <3 months in 2012, he was started on combined upfront androgen deprivation therapy with bicalutamide and goserelin. Subsequent therapies included enzalutamide plus an experimental prostate-specific antigen (PSA)-TRICOM viral vaccine (PROSTVAC), and docetaxel. Neuroendocrine differentiation was diagnosed by needle biopsy and the patient was treated with six cycles of carboplatin plus etoposide from April 2016 to September 2016.
On 09 November 2016, with progressive disease in the pelvis (enlargement of retroperitoneal lymphadenopathy), the patient enrolled on the Phase II QUADRUPLE THREAT clinical trial in which RRx-001 is dosed weekly intravenously until progression followed by rechallenge with platinum and etoposide.
The patient began weekly RRx-001 infusions on 23 November 2016. He received a second dose on 29 November and a third on 6 December 2016. On 7 December after three doses of RRx-001, the patient presented to the hospital with lower back pain. Magnetic resonance imaging (MRI) of the brain done at that time demonstrated lesions that had not been imaged previously (because baseline cranial imaging had not been required) and, the patient immediately received two weeks of whole brain radiation therapy.
The patient was reimaged with positron emission tomography/computed tomography (PET/CT) on 28 December 2016 and this scan showed RECIST evidence of progression in the previously documented retroperitoneal lymphadenopathy. There was significant enlargement and increased fluorodeoxyglucose (FDG) avidity of the retroperitoneal mass that was confluent with the left kidney, causing obstruction at the ureteropelvic junction. In addition, new liver lesions were discovered (Figure 2 ). RRx-001 was discontinued and the patient was transitioned back to carboplatin and etoposide rechallenge on 4 January 2017.
On 19 January, day 15 of his first cycle, the patient developed hematuria with urinary clotting, anemia (hemoglobin 7.1 g/dL), renal insufficiency (creatinine 1.42 mg/dL), and symptoms of obstruction. Over the month of January, 2017, these symptoms recurred, requiring two separate hospitalizations. Treatment for the hematuria, clotting, and anemia involved continuous bladder irrigation and red blood cell transfusion. After two cycles of platinum doublets, reimaging demonstrated a complete metabolic response on qualitative evaluation of FDG PET, even though his tumors were morphologically stable.
In addition, the hematuria and clotting subsided, the patient's quality of life drastically improved and the creatinine decreased from 1.42 to 1.2 mg/dL.
| DISCUSSION
An under-recognized diagnosis, treatment-emergent t-NEPC, which may result from androgen deprivation therapy, due to the preferential selection and outgrowth of NE clones, is an incurable and highly lethal disease subtype with no available standard options in the second line after treatment with platinum doublets. High rates of initial responses to platinum doublets are followed inevitably by the development of intractable resistance. RRx-001, a minimally toxic macrophage repolarizing agent with epigenetic properties, has been demonstrated to resensitize to previously tried and failed standard chemotherapies.
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In the Phase II QUADRUPLE THREAT trial, RRx-001 is administered as a pretreatment or primer until progression in patients with four tumor types, SCLC, ovarian cancer, neuroendocrine, andepidermal growth factor receptor (EGFR) mutated NSCLC, prior to rechallenge with platinum doublets. RRx-001 is an epigenetic inhibitor and dual checkpoint inhibitor of CD47-SIRPα inhibition, which repolarizes M2-like tumor-associated macrophages to M1-like macrophages. RRx-001, which has been associated with pseudoprogression 12 due to biopsy-proven immune cell infiltration, 13 edema, necrosis, and inflammation, appears to have elicited a similar pseudoprogressive enlargement of the tumors of this patient, (although in the absence of a biopsy, differentiating between true progressive disease and pseudoprogression is impossible), which might have suggested that he was in the throes of a death spiral rather than on the cusp of a complete metabolic response with platinum doublets. These cases serve as an object lesson that marked clinical deterioration and radiographic worsening do not necessarily equal treatment failure in RRx-001 patients, given the activity of RRx-001 as primer, which enhances responses to subsequent chemotherapies. 14, 15 Therefore, despite initial appearances of rapidly progressive disease after only three doses of RRx-001, which might otherwise and in another context have warranted a referral to hospice, the best decision for this patient was not to withdraw treatment but to continue it per protocol with reintroduced platinum doublets. In another patient on the QUADRUPLE THREAT trial with high-grade extrapulmonary neuroendocrine disease and a durable partial response to single agent RRx-001, documented elsewhere, 16 an increase in the size of his tumors preceded significant regression. Serial biopsies of his lesions demonstrated an influx of CD8 + lymphocytes, which appeared after 12 weeks.
In summary, given the absence of secondary salvage treatment options in t-NEPC, it is hoped that resensitization to initially highly effective platinum doublets after "priming" with RRx-001 will provide significant clinical benefit, even if as in the case of this patient rapid clinical worsening preceded it, and markedly change the bleak prognosis of this disease.
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